Amidst the artificial intelligence (AI) revolution and a rapidly shifting landscape in drug development, Recursion Pharmaceuticals (NASDAQ: RXRX) is aiming to position itself at the intersection of ...

The core problem Recursion seeks to solve is that the process of discovering and making new medicines is becoming slower and more costly over time, despite perpetually increasing knowledge of human ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

One reason Recursion Pharmaceuticals could become a big deal is that its goal is to usher a paradigm shift into the pharmaceutical industry. Even with impressive technological progress over the past ...

Recursion is scheduled to report its first quarter 2025 financial results, providing transparency and updates to investors, which can enhance trust and investor relations. The company'searnings ...

Oxford-based pharmaceutical firm Exscientia has agreed to an acquisition by Recursion, a biotech from Utah, US, in a transaction worth $688 million. The deal comes as major firms look to AI – as ...

Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug ...

Nvidia (NVDA), the Silicon Valley-based microprocessing giant with a growing presence in the life sciences, has spent the first three weeks of this year continuing its climb into the Wall Street ...

Operational complementarities expected to yield annual synergies of approximately $100 million ...